| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | AA | AB | AC | AD | AE | AF | AG | AH | AI | AJ | AK | AL | AM | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | ƒ | Categories | ||||||||||||||||||||||||||||||||||||||
2 | ||||||||||||||||||||||||||||||||||||||||
3 | Panels | Slide # | Category | Total Number of Entries | 1. Efficacy Testing | 2. Trained Workforce | 3. IAQ/ Public Health | 4. Standards & Guidelines | 5. Regulatory Guidance | 6. Proven Safety | 7. Proven Performmance | 8. Education Outreach | 9. Labeling Prod Info | 10. New Tech. Research | 11. Cost | 12. Far UV | 13. Installation Commissioning | 14. Collaboration | ||||||||||||||||||||||
4 | WH-OSTP | 2 | I-1 | Develop standard efficacy testing methods for air treatment technologies that promote appropriate labeling and informed use and enable high-quality, standardized, innovative products to come to market in a trusted manner. | ✓ | ✓ | ||||||||||||||||||||||||||||||||||
5 | WH-OSTP | 2 | I-2 | Conduct multidisciplinary epidemiological and implementation research on built environment technologies for reducing disease spread like GUV. | ✓ | ✓ | ||||||||||||||||||||||||||||||||||
6 | WH-OSTP | 2 | I-3 | Establish indoor air quality and built environment interventions like GUV as routine and significant parts of public health and epidemiological strategy | ✓ | ✓ | ||||||||||||||||||||||||||||||||||
7 | WH-OSTP | 3 | G-1 | Expand and train workforce for installation and maintenance of GUV installations | ✓ | |||||||||||||||||||||||||||||||||||
8 | WH-OSTP | 3 | G-2 | Develop more affordable form factors and fixtures for GUV including LED lights | ✓ | ✓ | ||||||||||||||||||||||||||||||||||
9 | WH-OSTP | 3 | G-3 | Support innovation in building and infrastructure design, indoor air quality monitors, pathogen sensors, advanced materials, and air disinfection technologies to foster healthy, safe and secure working, learning, and living environments for all | ✓ | ✓ | ||||||||||||||||||||||||||||||||||
10 | WH-OSTP | Total Entries = | 6 | 1 | 1 | 3 | 0 | 0 | 0 | 1 | 0 | 1 | 3 | 1 | 0 | 0 | 0 | |||||||||||||||||||||||
11 | PNNL | 5 | I-1 | Field evaluations/demonstrations to show technology is safe and effective | ✓ | ✓ | ✓ | |||||||||||||||||||||||||||||||||
12 | PNNL | 5 | I-2 | Guidelines + educated workforce to design, install, operate, maintain GUV systems in buildings | ✓ | ✓ | ||||||||||||||||||||||||||||||||||
13 | PNNL | 5 | I-3 | Validate and/or document safety of far-UV direct irradiation before deployment | ✓ | ✓ | ||||||||||||||||||||||||||||||||||
14 | PNNL | 6 | G-1 | Ensure safety of technology in occupiable spaces | ✓ | ✓ | ||||||||||||||||||||||||||||||||||
15 | PNNL | 6 | G-2 | Educated workforce to design, install, operate, and maintain | ✓ | ✓ | ||||||||||||||||||||||||||||||||||
16 | PNNL | 6 | G-3 | Clear guidelines/standards of most effective and efficient combinations of risk mitigation strategies (GUV, ventilation, room air cleaners, etc.) for IAQ and reduced disease transmission | ✓ | ✓ | ||||||||||||||||||||||||||||||||||
17 | PNNL | Total Entries = | 6 | 0 | 2 | 2 | 2 | 0 | 3 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | |||||||||||||||||||||||
18 | FDA | 8 | I-1 | Alignment on what are considered medical claims | ✓ | |||||||||||||||||||||||||||||||||||
19 | FDA | 8 | I-2 | Addressing ongoing pandemic concerns | ✓ | |||||||||||||||||||||||||||||||||||
20 | FDA | 9 | G-1 | Continue to collaborate with the agency to bring safe and effective products to the market | ✓ | ✓ | ✓ | ✓ | ||||||||||||||||||||||||||||||||
21 | FDA | Total Entries = | 3 | 1 | 0 | 2 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | |||||||||||||||||||||||
22 | CDC/NIOSH | 11 | I-1 | Continuing to understand the role UV technologies can play throughout local, state, and federal government agencies | ✓ | ✓ | ||||||||||||||||||||||||||||||||||
23 | CDC/NIOSH | 11 | I-2 | Decoupling UV air treatment from UV surface disinfection | ✓ | ✓ | ||||||||||||||||||||||||||||||||||
24 | CDC/NIOSH | 11 | I-3 | Improving guidance for design, installation, commissioning, operation and periodic performance validation | ✓ | ✓ | ✓ | |||||||||||||||||||||||||||||||||
25 | CDC/NIOSH | 11 | I-4 | Documenting successful in-duct UV air treatment case studies | ✓ | ✓ | ||||||||||||||||||||||||||||||||||
26 | CDC/NIOSH | 12 | G-1 | Increase knowledge about the benefits/limitations of far UV | ✓ | ✓ | ||||||||||||||||||||||||||||||||||
27 | CDC/NIOSH | 12 | G-2 | Enhance design, installation and operation guidance | ✓ | ✓ | ✓ | |||||||||||||||||||||||||||||||||
28 | CDC/NIOSH | 12 | G-2.1 | Focus on end-users and decision makers | ✓ | |||||||||||||||||||||||||||||||||||
29 | CDC/NIOSH | 12 | G-2.2 | Cover all accepted/proven UV technologies | ✓ | ✓ | ✓ | ✓ | ||||||||||||||||||||||||||||||||
30 | CDC/NIOSH | 12 | G-2.3 | Establish proven, user-friendly performance verification protocols | ✓ | ✓ | ✓ | ✓ | ||||||||||||||||||||||||||||||||
31 | CDC/NIOSH | 12 | G-2.4 | Provide credentialing for system designers/installers | ✓ | ✓ | ||||||||||||||||||||||||||||||||||
32 | CDC/NIOSH | 12 | G-3 | Take steps toward standard testing and regulation | ✓ | ✓ | ✓ | |||||||||||||||||||||||||||||||||
33 | CDC/NIOSH | Total Entries = | 11 | 3 | 2 | 1 | 6 | 3 | 0 | 1 | 5 | 0 | 0 | 0 | 1 | 4 | 2 | |||||||||||||||||||||||
34 | NIST | 14 | I-1 | Consensus-based standards and test methods | ✓ | ✓ | ||||||||||||||||||||||||||||||||||
35 | NIST | 14 | I-2 | Consistent approaches to conformity assessment | ✓ | ✓ | ✓ | ✓ | ||||||||||||||||||||||||||||||||
36 | NIST | 14 | I-3 | Stakeholder awareness | ✓ | |||||||||||||||||||||||||||||||||||
37 | NIST | 15 | G-1 | Sound, widely-accepted standards and test methods for determining efficacy and safety | ✓ | ✓ | ✓ | ✓ | ||||||||||||||||||||||||||||||||
38 | NIST | 15 | G-2 | Coordination among public and private sector stakeholders | ✓ | ✓ | ||||||||||||||||||||||||||||||||||
39 | NIST | 15 | G-3 | Framework for how to leverage progress when addressing the next challenge | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||||||||||||||||||||||||||
40 | NIST | Total Entries = | 6 | 3 | 0 | 1 | 4 | 2 | 1 | 1 | 3 | 1 | 0 | 0 | 0 | 0 | 2 | |||||||||||||||||||||||
41 | OSHA | 17 | I-1 | Universal performance metric –under which conditions will GUV produce IAQ making fewer people sick | ✓ | ✓ | ✓ | ✓ | ||||||||||||||||||||||||||||||||
42 | OSHA | 17 | I-2 | Universal safety metric –UV dosing under which conditions is safe for workers | ✓ | ✓ | ✓ | |||||||||||||||||||||||||||||||||
43 | OSHA | 147 | I-3 | Development of measurement techniques for the 2 issues above | ✓ | ✓ | ✓ | ✓ | ||||||||||||||||||||||||||||||||
44 | OSHA | 18 | G-1 | OSHA is actively partnering with academic and governmental groups to support the development of performance and measuring standards | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||||||||||||||||||||||||||
45 | OSHA | Total Entries = | 4 | 3 | 0 | 4 | 4 | 1 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | |||||||||||||||||||||||
46 | EPA | 27 | I-1 | EPA faces many challenges in regulating devices because the current regulatory framework does not allow for pre-market review of product safety or efficacy claims and does not address the complexity of devices available on the market today. | ✓ | ✓ | ✓ | |||||||||||||||||||||||||||||||||
47 | EPA | 27 | I-2 | Resource constraints limit the ability to undertake regulatory changes at this time. | ✓ | ✓ | ||||||||||||||||||||||||||||||||||
48 | EPA | 27 | I-3 | Device products with claims to control SARS-CoV-2 have continued to expand during the pandemic. | ✓ | ✓ | ||||||||||||||||||||||||||||||||||
49 | EPA | 28 | I-4 | Public health consequences for insufficiently regulated devices. | ✓ | ✓ | ✓ | |||||||||||||||||||||||||||||||||
50 | EPA | 28 | 1-4.1 | Users may not use prudent disinfection processes if they believe they are protected by these technologies. | ✓ | ✓ | ✓ | |||||||||||||||||||||||||||||||||
51 | EPA | 28 | 1-4.2 | Users may believe they do not have to follow public health guidance, such as handwashing, wearing masks, social distancing, etc. | ✓ | ✓ | ✓ | ✓ | ||||||||||||||||||||||||||||||||
52 | EPA | 28 | 1.5 | Some devices may cause harm: | ✓ | ✓ | ✓ | |||||||||||||||||||||||||||||||||
53 | EPA | 28 | 1.5.1 | Some UV lights can causeburns of skin/eyes, skin cancer. | ✓ | ✓ | ✓ | |||||||||||||||||||||||||||||||||
54 | EPA | 28 | 1.5.2 | Some UV light devices generate ozone which can exacerbate asthma and chronic obstructive pulmonary disease. | ✓ | ✓ | ✓ | |||||||||||||||||||||||||||||||||
55 | EPA | Total Entries = | 9 | 2 | 0 | 3 | 0 | 2 | 6 | 1 | 6 | 4 | 1 | 1 | 0 | 0 | 0 | |||||||||||||||||||||||
56 | Federal Panelists | # (Total = 45) | 45 | 45 | 13 | 5 | 16 | 16 | 8 | 12 | 8 | 15 | 6 | 4 | 2 | 2 | 5 | 6 | ||||||||||||||||||||||
57 | % | 100% | 28.9% | 11.1% | 35.6% | 35.6% | 17.8% | 26.7% | 17.8% | 33.3% | 13.3% | 8.9% | 4.4% | 4.4% | 11.1% | 13.3% | ||||||||||||||||||||||||
58 | ||||||||||||||||||||||||||||||||||||||||
59 | P-1: Donsky | 31 | I.1 | Candida auris | ✓ | ✓ | ✓ | |||||||||||||||||||||||||||||||||
60 | P-1: Donsky | 31 | I.1.1 | Environment is important | ✓ | ✓ | ✓ | |||||||||||||||||||||||||||||||||
61 | P-1: Donsky | 31 | I.1.2 | Manual cleaning suboptimal | ✓ | ✓ | ✓ | |||||||||||||||||||||||||||||||||
62 | P-1: Donsky | 31 | I.1.3 | UV-C effective | ✓ | ✓ | ✓ | |||||||||||||||||||||||||||||||||
63 | P-1: Donsky | 31 | I.2 | Why is UV not being used? | ✓ | ✓ | ✓ | ✓ | ||||||||||||||||||||||||||||||||
64 | P-1: Donsky | 31 | I.2.1 | Cost | ✓ | ✓ | ✓ | |||||||||||||||||||||||||||||||||
65 | P-1: Donsky | 31 | I.2.2 | Ease of use | ✓ | ✓ | ✓ | |||||||||||||||||||||||||||||||||
66 | P-1: Donsky | 31 | I.2.3 | Evidence | ✓ | ✓ | ✓ | |||||||||||||||||||||||||||||||||
67 | P-1: Donsky | 31 | I.2.4 | CDC recommendations and practice guidelines | ✓ | ✓ | ✓ | ✓ | ||||||||||||||||||||||||||||||||
68 | P-1: Donsky | 32 | G.1 | Do-it-yourself test protocol | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||||||||||||||||||||||||||
69 | P-1: Donsky | 32 | G.1.1 | Commercial biological indicator spores | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||||||||||||||||||||||||||||
70 | P-1: Donsky | 32 | G.1.2 | Simple, standard exposure protocol | ✓ | ✓ | ✓ | ✓ | ||||||||||||||||||||||||||||||||
71 | P-1: Donsky | 32 | G.1.3 | Process in-house or send to commercial lab for testing | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||||||||||||||||||||||||||||
72 | P-1: Donsky | 32 | G.2 | Compare Devices | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||||||||||||||||||||||||||||
73 | P-1: Donsky | 3 | G.3 | Cost | ✓ | ✓ | ✓ | |||||||||||||||||||||||||||||||||
74 | P-1: Donsky | 32 | G.4 | Evidence | ✓ | ✓ | ||||||||||||||||||||||||||||||||||
75 | P-1: Donsky | Total Entries = | 16 | 10 | 0 | 12 | 8 | 5 | 1 | 8 | 10 | 0 | 0 | 3 | 0 | 0 | 4 | |||||||||||||||||||||||
76 | P-1: Mathew | 34 | I.1 | Infection prevention principles are the building blocks for safer healthcare delivery | ✓ | ✓ | ✓ | ✓ | ||||||||||||||||||||||||||||||||
77 | P-1: Mathew | 34 | I.2 | Challenges in resilient healthcare staffing and systems | ✓ | ✓ | ✓ | |||||||||||||||||||||||||||||||||
78 | P-1: Mathew | 34 | I.3 | Turnover of staff/ EVS: requires frequent training and monitoring/ assessment of any drift in cleaning techniques | ✓ | ✓ | ✓ | ✓ | ||||||||||||||||||||||||||||||||
79 | P-1: Mathew | 34 | I.4 | Rise in antimicrobial resistance (AMR)/ novel pathogens | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||||||||||||||||||||||||||||
80 | P-1: Mathew | 34 | I.5 | Impact of climate change and spread of soil microbes with AMR (floods leading to soil erosions- with exposures and impacting plants/animals and humans) | ✓ | ✓ | ✓ | |||||||||||||||||||||||||||||||||
81 | P-1: Mathew | 35 | G.1 | Devices and tools that are automated (less prone to human errors/ drifts in human techniques) | ✓ | ✓ | ✓ | ✓ | ||||||||||||||||||||||||||||||||
82 | P-1: Mathew | 35 | G.2 | Need to tap into AI- gather data and provide real time feedback | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||||||||||||||||||||||||||
83 | P-1: Mathew | 35 | G.3 | UV Devices that are safe in healthcare settings (both in acute care and in Long Term Acute Care and Skilled Nursing facilities | ✓ | ✓ | ✓ | ✓ | ||||||||||||||||||||||||||||||||
84 | P-1: Mathew | 35 | G.4 | Devices for other industries : travel and hospitality (global utilization to decrease spread of AMR through land transport/planes/ships) | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||||||||||||||||||||||||
85 | P-1: Mathew | 35 | G.5 | Devices for Community centers/places of worship/recreation/museums/music/opera (singing = airborne spread) | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||||||||||||||||||||||||
86 | P-1: Mathew | 35 | G.6 | Cost effective and access by communities currently faced with health inequities and limited access to healthcare | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||||||||||||||||||||||||||||
87 | P-1: Mathew | Total Entries = | 11 | 4 | 2 | 11 | 5 | 1 | 3 | 4 | 5 | 2 | 4 | 1 | 0 | 2 | 9 | |||||||||||||||||||||||
88 | P-1: Blatchley | 37 | I.1 | Lack of standards for design, validation/testing | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||||||||||||||||||||||||
89 | P-1: Blatchley | 37 | I.1.1 | Quantitative link between system characteristics and performance (risk-based approach) | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||||||||||||||||||||
90 | P-1: Blatchley | 37 | I.2 | Optimization of UVC exposure | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||||||||||||||||||||||||
91 | P-1: Blatchley | 37 | I.2.1 | Disinfection vs. human exposure | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||||||||||||||||||||||||
92 | P-1: Blatchley | 37 | I.3 | Need for new, efficient UVC sources | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||||||||||||||||||||||||||
93 | P-1: Blatchley | 37 | I.3.1 | Higher output power, wavelength selection | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||||||||||||||||||||||||||||
94 | P-1: Blatchley | 38 | G.1 | Develop standards for design, testing/validation | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||||||||||||||||||||||||||
95 | P-1: Blatchley | 38 | G.2 | Develop new, efficient UV sources | ✓ | ✓ | ✓ | ✓ | ||||||||||||||||||||||||||||||||
96 | P-1: Blatchley | 38 | G.3 | Develop UV-based applications across scales | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||||||||||||||||||||||||||
97 | P-1: Blatchley | Total Entries = | 9 | 9 | 0 | 8 | 7 | 7 | 6 | 6 | 5 | 5 | 7 | 2 | 2 | 0 | 8 | |||||||||||||||||||||||
98 | P-1: McPhaul | 40 | I.1 | Communication to the public about its effectiveness: Does it work? | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ||||||||||||||||||||||||||||
99 | P-1: McPhaul | 40 | I.2 | Communication about its safety: Is it safe? Even for children, older adults, the medically fragile and those who are immune compromised? | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||||||||||||||||||||||||||
100 | P-1: McPhaul | 40 | I.3 | Who should I believe when considering GUV? | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |||||||||||||||||||||||||||||